Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects
Primary Purpose
Non-Insulin-dependent Diabetes Mellitus
Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
placebo
3.4 g psyllium BID
6.8g psyllium BID
Sponsored by

About this trial
This is an interventional basic science trial for Non-Insulin-dependent Diabetes Mellitus focused on measuring Type II NIDDM
Eligibility Criteria
Inclusion Criteria:
- Have a clinical diagnosis of Type II diabetes mellitus, controlled by diet and/or second generation oral hypoglycemic drugs, with the onset of the disease after age 35.
- Are between 0 and 50% above "normal" body weight (adjusted by frame) according to the Metropolitan Life Insurance Tables.
- Are male or female, aged 36-80 years with a diagnosis made at least 1 year prior to enrollment.
- Have an HbA1c level between 6 and 10%
- Have a fasting serum glucose level between 120-220 mg/dL and not vary by more than ±20% during the month prior to entering the treatment phase and HbA1c levels not vary by more than ±10% during the month prior to entering the treatment phase. Serum glucose level must have been between 120-220mg/dl and the subject's HbA1c between 6 and 10% at Week 0.
- Have been on a "stable" diet consistent with ADA-recommended dietary guidelines with intake of total dietary fiber < 15g/1000 calories and were willing to maintain this diet during the 20-week study.
- Have maintained a constant body weight (±5%) during the month prior to entering the treatment phase
Exclusion Criteria:
- Have a condition that would interfere with evaluation
Sites / Locations
- University of Miami, Diabetes Unit D-1
- International Diabetes Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Active Comparator
Active Comparator
Arm Label
placebo
psyllium 3.4g BID
6.8g psyllium BID
Arm Description
matched placebo BID
3.4g psyllium BID for a Total of 6.8g daily
6.8g psyllium BID for a total of 13.6 g/day
Outcomes
Primary Outcome Measures
Change From Baseline in Fasting Glucose
Change from Baseline is defined as the Post-Baseline value subtracted from the Baseline value
Change From Baseline in Fasting HbA1c
Change is defined as Post-Baseline minus Baseline
Change From Baseline in Fasting HDL Cholesterol
Change is defined as Post-Baseline minus Baseline
Change From Baseline in Fasting LDL Cholesterol
Change is defined as Post-Baseline minus Baseline
Total Cholesterol Change From Baseline
Change is defined as Post-Baseline minus Baseline
Triglyceride Change From Baseline
Change is defined as Post-Baseline minus Baseline
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01582282
Brief Title
Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects
Official Title
A Clinical Study to Determine the Ability of Metamucil to Reduce Fasting Blood Glucose and HbA1c Levels in Type II NIDDM
Study Type
Interventional
2. Study Status
Record Verification Date
November 2012
Overall Recruitment Status
Terminated
Why Stopped
due to slow enrollment
Study Start Date
May 1988 (undefined)
Primary Completion Date
January 1990 (Actual)
Study Completion Date
January 1990 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Procter and Gamble
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
A double-blind, randomized, placebo-controlled, multi-dose clinical study consisting of 2 phases; 1) an 8-week lead-in period during which patients followed a diet judged to be within the acceptable guidelines of the ADA, and 2) a 12-week treatment period, at the beginning of which, Subjects are randomly assigned to 1 of the 3 treatment groups: placebo, 3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil) or 6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil). For 12 weeks, Subjects took Metamucil or the fiber-free placebo BID, just prior to breakfast and dinner.
Patients visited the clinic 10 times during the 20-week period at Screening, Weeks -8, -6, -4, 0, Day 3, and Weeks 2, 4, 8 and 12, fasting at least 12 hours prior to each visit where a blood sample was taken (all visits except Week -6 and Day 3) for analysis of fasting serum glucose and lipid levels, and HbA1c. Clinical chemistry, hematology and urinalysis were done at Weeks -8, 0 and 12. The completed 7-day food diaries were reviewed by the study dietician at each visit and discussed with the patient to ensure compliance with the recommended diet and the patients' body weights were recorded
Detailed Description
During the first phase, lead-in period during Subjects followed a diet judged to be within the acceptable guidelines of the ADA, with compliance assessed by a study dietician using 7-day food diaries completed by the patients. Subject body weight, serum glucose and serum HbA1c, and lipid levels were allowed to stabilize during this period.
During the 12-week treatment period, Subjects were stratified by either diet alone or diet and oral hypoglycemic medication and randomly assigned to 1 of the 3 treatment groups: placebo, 3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil) or 6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil). For 12 weeks, patients took Metamucil or the fiber-free placebo BID, just prior to breakfast and dinner.
Patients visited the clinic 10 times during the 20-week period at Screening, Weeks -8, -6, -4, 0, Day 3, and Weeks 2, 4, 8 and 12, fasting at least 12 hours prior to each visit where a blood sample was taken (all visits except Week -6 and Day 3) for analysis of fasting serum glucose and lipid levels, and HbA1c. Clinical chemistry, hematology and urinalysis were done at Weeks -8, 0 and 12. The completed 7-day food diaries were reviewed by the study dietician at each visit and discussed with the patient to ensure compliance with the recommended diet and the patients' body weights were recorded.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Insulin-dependent Diabetes Mellitus
Keywords
Type II NIDDM
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
37 (Actual)
8. Arms, Groups, and Interventions
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
matched placebo BID
Arm Title
psyllium 3.4g BID
Arm Type
Active Comparator
Arm Description
3.4g psyllium BID for a Total of 6.8g daily
Arm Title
6.8g psyllium BID
Arm Type
Active Comparator
Arm Description
6.8g psyllium BID for a total of 13.6 g/day
Intervention Type
Dietary Supplement
Intervention Name(s)
placebo
Intervention Description
fiber-free placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
3.4 g psyllium BID
Other Intervention Name(s)
Metamucil
Intervention Description
3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil)
Intervention Type
Dietary Supplement
Intervention Name(s)
6.8g psyllium BID
Other Intervention Name(s)
Metamucil
Intervention Description
6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil)
Primary Outcome Measure Information:
Title
Change From Baseline in Fasting Glucose
Description
Change from Baseline is defined as the Post-Baseline value subtracted from the Baseline value
Time Frame
12 weeks
Title
Change From Baseline in Fasting HbA1c
Description
Change is defined as Post-Baseline minus Baseline
Time Frame
12 weeks
Title
Change From Baseline in Fasting HDL Cholesterol
Description
Change is defined as Post-Baseline minus Baseline
Time Frame
12 weeks
Title
Change From Baseline in Fasting LDL Cholesterol
Description
Change is defined as Post-Baseline minus Baseline
Time Frame
12 weeks
Title
Total Cholesterol Change From Baseline
Description
Change is defined as Post-Baseline minus Baseline
Time Frame
12 weeks
Title
Triglyceride Change From Baseline
Description
Change is defined as Post-Baseline minus Baseline
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
36 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Have a clinical diagnosis of Type II diabetes mellitus, controlled by diet and/or second generation oral hypoglycemic drugs, with the onset of the disease after age 35.
Are between 0 and 50% above "normal" body weight (adjusted by frame) according to the Metropolitan Life Insurance Tables.
Are male or female, aged 36-80 years with a diagnosis made at least 1 year prior to enrollment.
Have an HbA1c level between 6 and 10%
Have a fasting serum glucose level between 120-220 mg/dL and not vary by more than ±20% during the month prior to entering the treatment phase and HbA1c levels not vary by more than ±10% during the month prior to entering the treatment phase. Serum glucose level must have been between 120-220mg/dl and the subject's HbA1c between 6 and 10% at Week 0.
Have been on a "stable" diet consistent with ADA-recommended dietary guidelines with intake of total dietary fiber < 15g/1000 calories and were willing to maintain this diet during the 20-week study.
Have maintained a constant body weight (±5%) during the month prior to entering the treatment phase
Exclusion Criteria:
Have a condition that would interfere with evaluation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Reeves, MD
Organizational Affiliation
University of Miami
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Richard Bergenstal, MD
Organizational Affiliation
International Diabetes Center, Minneapolis, MN 55416
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Miami, Diabetes Unit D-1
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
International Diabetes Center
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55416
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects
We'll reach out to this number within 24 hrs